Welcome to In Cell Art
| The sequencing of the human genome continues to reveal the genetic basis for numerous diseases leading to the identification of macromolecular drugs (DNA, RNAi, peptides, proteins) that would have a significant impact on human health. With this wealth of information the ability to design patient-specific drugs that alter the cellular machinery in a way that controls or treats a specific disease will increasingly become a reality.Designing macromolecular drugs as well as engineering novel delivery vectors that effectively transport macromolecular drugs provides an opportunity to enhance the understanding of disease mechanisms and may help treat these diseases. In-Cell-Art has developed cutting edge nanocarriers that actively transport macromolecules into cells. In-Cell-Art is motivated by the widespread applications for the human health. By B. Pitard |
Collaborations and publications
Dec 07, 2009: In Cell Art has announced that it has expanded its research collaboration agreement with Sanofi Pasteur in order to pursue the evaluation of In Cell Art nanocarrier technologies in the context of Sanofi Pasteur’s vaccines programme.
Oct 08, 2008: In Cell Art nanocapsules, designed for hepatocyte-targeted DNA delivery, are published in the Journal of Gene medecine
Sept 08, 2008: In Cell Art and Sanofi Pasteur enter into research collaboration agreement for the evaluation of In Cell Art technologies.
News
Our products
ICAFectin™ 441 for DNAThe reagent of choice for primary and stem cells DNA transfection
Product informations
ICAFectin™ 442 for siRNAHighly efficient gene silencing with very few siRNA quantities
Product information
ICAntibodiesGenetic immunization: from gene to antibody
Your Solution for DNA-based antibody generation
